PE
SGMO

Point72 Europe’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Point72 Europe’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$468 Buy
+695
New +$375 ﹤0.01% 709

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Point72 Europe's SGMO Position: Q3 2025 in Review

Point72 Europe opened a new position in SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025: 695 shares worth $468. The stake represents ﹤0.01% of the portfolio and ranks #709 among its holdings.

112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.

  • Point72 Europe held 695 shares of SANGAMO THERAPEUTICS INC worth $468 as of Q3 2025.
  • SANGAMO THERAPEUTICS INC was a new Point72 Europe position in Q3 2025.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #709 holding.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.